NCT02389907

Brief Summary

Assessing the association between patients' perceptions of success with post-operative pain management and overall experience with care.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jun 2015

Shorter than P25 for all trials

Geographic Reach
1 country

9 active sites

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 2, 2015

Completed
15 days until next milestone

First Posted

Study publicly available on registry

March 17, 2015

Completed
3 months until next milestone

Study Start

First participant enrolled

June 1, 2015

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2015

Completed
Last Updated

April 26, 2018

Status Verified

April 1, 2018

Enrollment Period

2 months

First QC Date

March 2, 2015

Last Update Submit

April 24, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Patient Global Assessment (PGA) and Hospital Consumer Assessment of Healthcare providers and Systems (HCAHPS)

    Assess the association between patients' perceptions of success with opioid post-operative pain management following total hip replacement or hysterectomy surgery as measured by a patient global assessment (PGA) at 24 hours post-op and at 48 hours post-op, and their perception of pain management while in the hospital and the hospital overall, as measured by the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) instrument two-weeks (14 days) post-discharge

    24 hours - 14 days post discharge

Secondary Outcomes (1)

  • Post-Operative Pain Management Modality

    14 days post discharge

Other Outcomes (1)

  • Composite outcome measures consisting of multiple measures

    48 Hours Post Op

Study Arms (2)

Total Hip Replacement Group

Adults who have undergone a total hip replacement

Hysterectomy Group

Adults who have undergone a hysterectomy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Study population will include adults 18 years of age or older who have undergone either a total hip replacement or hysterectomy.

You may qualify if:

  • Subject must be 18 years of age or older
  • Subject (or their legally acceptable representative) must have signed an informed consent form (ICF) indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
  • Subject is receiving a unilateral total hip replacement or a hysterectomy (total abdominal hysterectomy, total abdominal hysterectomy/bilateral salpingo-oophorectomy, total vaginal hysterectomy, or total vaginal hysterectomy/salpingo-oophorectomy)
  • Subject is expected to remain hospitalized for at least 24 hours post-operatively
  • Subject is expected to experience pain requiring IV PCA or non-PCA (non-patient controlled opioids via IV, IM, SC, or PO routes of administration) opioids for at least 24 hours after surgery
  • Subject is classified as American Society of Anesthesiology (ASA) category I, II, or III
  • Subject is willing to complete the required post-operative survey measures to be completed in the hospital
  • Subject is willing to complete a post-discharge survey (including HCAHPS survey instrument) via telephone approximately two-weeks (14 days) post-discharge

You may not qualify if:

  • Subject cannot read, write, and communicate in English
  • Subject has a history of tolerance to opioids including those prescribed opioids in the 3 month period leading up to the perioperative period (i.e., a subject is considered to have a potential tolerance to opioids if for 4 consecutive days prior to surgery they have been taking a short acting/short acting combination opioid analgesic greater than 120 mg codein daily, 40 mg hydrocodone daily, 200 mg tramadol daily, or 40 mg oxycodone daily or if they were on any dose of strong opioid analgesic such as morphine, hydromorphone, or fentanyl)
  • Subject has a history of allergy to opioids reported pre-operatively or documented in medical history
  • Subject is scheduled to receive additional surgical procedures beyond those listed within 72 hours of the initial surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Bridgeport Hospital

Bridgeport, Connecticut, 06610, United States

Location

Jupiter Medical Center

Jupiter, Florida, 33458, United States

Location

Phoenix Clinical Research LLC

Tamarac, Florida, 33321, United States

Location

Henry Ford Health System

Detroit, Michigan, 48202, United States

Location

Orthopaedic Associates of Michigan

Grand Rapids, Michigan, 49525, United States

Location

Drexel University

Philadelphia, Pennsylvania, 19104, United States

Location

Magee-Women's Hospital (UPMC)

Pittsburgh, Pennsylvania, 15213, United States

Location

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15232, United States

Location

Baylor Health Research Institute

Fort Worth, Texas, 76104, United States

Location

Related Publications (2)

  • Cohen J. A power primer. Psychol Bull. 1992 Jul;112(1):155-9. doi: 10.1037//0033-2909.112.1.155.

  • Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Earlbaum Associates.

    RESULT

MeSH Terms

Conditions

Pain, Postoperative

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Officials

  • Jeffrey Abraham, MSPT, MBA

    The Medicines Company

    STUDY DIRECTOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
14 Days
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 2, 2015

First Posted

March 17, 2015

Study Start

June 1, 2015

Primary Completion

August 1, 2015

Study Completion

August 1, 2015

Last Updated

April 26, 2018

Record last verified: 2018-04

Locations